Eli Lilly joined a $50 million investment in Caspian Therapeutics, a biotech startup spun out from Kura Oncology. The company develops small-molecule menin inhibitors for metabolic diseases. This approach aims to regenerate the pancreas and treat the underlying causes of diabetes. Caspian expects its first drug candidate to enter Phase 1 trials by 2028.
A federal judge partially trimmed Eli Lilly’s lawsuit against telehealth provider Mochi Health regarding compounded versions of Zepbound and Mounjaro. While the judge dismissed several claims, unfair competition charges against Aequita Pharmacy will proceed. The ruling supports Lilly’s strategy to protect its weight-loss franchises from unauthorized compounded alternatives.